Sartorius Stedim Biotech Shares Drop 2.68% to €159.90, Below Moving Averages

A Stock Struggling to Break Out of a Fundamental Downtrend

The price is trading below its three moving averages. The MM20 (€169.57) and MM50 (€169.14) are more than 5% above the current price, while the MM200 (€185.75) remains nearly 14% away. This alignment indicates a bearish dynamic entrenched for several months, confirmed by a 21% decline over the year.

In the Bollinger Bands, the stock is positioned in the lower 31% of the range, yet without returning to the lower boundary at €144.38. The RSI at 47 remains neutral, which rules out an immediate oversold reading despite today's decline. The technical support identified at €151.50 remains the reference level for further declines.

The session on May 5 had allowed the price to move back above €159 after the late April low at €153. Today's rebound is losing momentum.

Tight Valuation and Summer Schedule for the Next Step

Based on the consensus of ten analysts, the stock is trading at approximately 31.6 times the expected earnings for the current fiscal year and 26.4 times those of 2027. The average for the Health Care sector is 19 times. Earnings per share growth is anticipated at 20% year-over-year, which justifies part of the premium, but keeps the valuation at a demanding level.

The sector context remains marked by margin pressures. During the first quarter 2026 release on April 23, the group reported a revenue increase of 7.9% at constant exchange rates, to €762 million, but a slight decline in regular EBITDA margin to 30.7%. Tariffs and the macroeconomic environment were cited as pressure factors.

The next financial calendar appointment is set for July 23, 2026, with the publication of the half-year results. Until then, the support at €151.50 remains the reference low level for the stock.